Payment overview · 2025
General Payments
$576.21
26 reported records · 10 companies
Healthcare provider profile · identity verified
Mohd A Hossain, M.D
Allopathic & Osteopathic Physicians|Internal Medicine · HOLLIS, NY · NPI 1083931919
Verified facts
What the public records show
CMS Open Payments records show Mohd A Hossain, M.D received $576.21 in general payments during 2025 across 26 reported records.
Phathom Pharmaceuticals, Inc. accounted for 24.8% of that reported general-payment amount.
The Open Payments records used for this analysis explicitly named 15 associated products.
A separate comparison found the same explicitly named product in public Medicare Part D data: Linzess, Ozempic.
ABBVIE INC. reported payments to this doctor in 2025. Across the 2025 Open Payments General Payment records loaded for this analysis, that same reporting entity reported LINZESS as an associated drug or biological on 87954 records involving 21815 distinct recipient NPIs. Public Medicare Part D data also shows 62 claims for Linzess by this doctor in 2024.
AstraZeneca Pharmaceuticals LP reported payments to this doctor in 2025. Across the 2025 Open Payments General Payment records loaded for this analysis, that same reporting entity reported FARXIGA as an associated drug or biological on 106133 records involving 42906 distinct recipient NPIs. Public Medicare Part D data also shows 102 claims for Farxiga by this doctor in 2024.
AstraZeneca Pharmaceuticals LP reported payments to this doctor in 2025. Across the 2025 Open Payments General Payment records loaded for this analysis, that same reporting entity reported SYMBICORT as an associated drug or biological on 71 records involving 51 distinct recipient NPIs. Public Medicare Part D data also shows 12 claims for Symbicort by this doctor in 2024.
Lilly USA, LLC reported payments to this doctor in 2025. Across the 2025 Open Payments General Payment records loaded for this analysis, that same reporting entity reported JARDIANCE as an associated drug or biological on 47708 records involving 23833 distinct recipient NPIs. Public Medicare Part D data also shows 266 claims for Jardiance by this doctor in 2024.
Lilly USA, LLC reported payments to this doctor in 2025. Across the 2025 Open Payments General Payment records loaded for this analysis, that same reporting entity reported TRULICITY as an associated drug or biological on 71 records involving 57 distinct recipient NPIs. Public Medicare Part D data also shows 23 claims for Trulicity by this doctor in 2024.
Novo Nordisk Inc reported payments to this doctor in 2025. Across the 2025 Open Payments General Payment records loaded for this analysis, that same reporting entity reported Ozempic as an associated drug or biological on 261625 records involving 77793 distinct recipient NPIs. Public Medicare Part D data also shows 20 claims for Ozempic by this doctor in 2024.
These records do not establish that a payment influenced prescribing or medical care.
Separate record types
Research & Ownership
Research Payments (direct recipient): not present in the loaded data
Associated Research Funding (for example, named PI): not present in the loaded data
Ownership / Investment: not present in the loaded data
These categories are never added into the General Payments headline. Associated research funding must not be described as money the doctor personally received unless the source record supports that conclusion.
Who paid this doctor?
Companies in 2025 General Payments
| Reported company | Canonical company | Amount | Share | Records | Year |
|---|---|---|---|---|---|
| Phathom Pharmaceuticals, Inc. | Unresolved — no canonical attribution shown | $142.97 | 24.8% | 6 | 2025 |
| SHIELD THERAPEUTICS INC | Unresolved — no canonical attribution shown | $93.99 | 16.3% | 5 | 2025 |
| Lilly USA, LLC | Unresolved — no canonical attribution shown | $93.06 | 16.1% | 4 | 2025 |
| AstraZeneca Pharmaceuticals LP | Unresolved — no canonical attribution shown | $51.47 | 8.9% | 2 | 2025 |
| Mannkind Corporation | Unresolved — no canonical attribution shown | $50.01 | 8.7% | 2 | 2025 |
| Novo Nordisk Inc | Unresolved — no canonical attribution shown | $43.74 | 7.6% | 2 | 2025 |
| Amgen Inc. | Unresolved — no canonical attribution shown | $40.01 | 6.9% | 2 | 2025 |
| ABBVIE INC. | Unresolved — no canonical attribution shown | $23.86 | 4.1% | 1 | 2025 |
| GlaxoSmithKline, LLC. | Unresolved — no canonical attribution shown | $21.19 | 3.7% | 1 | 2025 |
| Abbott Laboratories | Unresolved — no canonical attribution shown | $15.91 | 2.8% | 1 | 2025 |
What were the payments for?
Payment categories
| Category | Amount | Records |
|---|---|---|
| Food and Beverage | $576.21 | 26 |
A meal, consulting fee, royalty, and travel payment describe different kinds of reported relationships and should not be interpreted as equivalent.
Analysis 1 · Payment-linked products
Products named in Open Payments records
| Reported product | Type | Reported company | Related amount* | Records | Year |
|---|---|---|---|---|---|
| VOQUEZNA Normalized: voquezna |
Drug | Phathom Pharmaceuticals, Inc. | $142.97 | 6 | 2025 |
Source payment records
|
|||||
| ACCRUFER Normalized: accrufer |
Drug | SHIELD THERAPEUTICS INC | $93.99 | 5 | 2025 |
Source payment records
|
|||||
| MOUNJARO Normalized: mounjaro |
Drug | Lilly USA, LLC | $93.06 | 4 | 2025 |
Source payment records
|
|||||
| ZEPBOUND Normalized: zepbound |
Drug | Lilly USA, LLC | $93.06 | 4 | 2025 |
Source payment records
|
|||||
| AFREZZA Normalized: afrezza |
Drug | Mannkind Corporation | $50.01 | 2 | 2025 |
Source payment records
|
|||||
| Ozempic Normalized: ozempic |
Drug | Novo Nordisk Inc | $43.74 | 2 | 2025 |
Source payment records
|
|||||
| Rybelsus Normalized: rybelsus |
Drug | Novo Nordisk Inc | $43.74 | 2 | 2025 |
Source payment records
|
|||||
| OTEZLA Normalized: otezla |
Drug | Amgen Inc. | $40.01 | 2 | 2025 |
Source payment records
|
|||||
| REPATHA Normalized: repatha |
Biological | Amgen Inc. | $40.01 | 2 | 2025 |
Source payment records
|
|||||
| BREZTRI Normalized: breztri |
Drug | AstraZeneca Pharmaceuticals LP | $31.76 | 1 | 2025 |
Source payment records
|
|||||
| CREON Normalized: creon |
Drug | ABBVIE INC. | $23.86 | 1 | 2025 |
Source payment records
|
|||||
| LINZESS Normalized: linzess |
Drug | ABBVIE INC. | $23.86 | 1 | 2025 |
Source payment records
|
|||||
| TRELEGY ELLIPTA Normalized: trelegy ellipta |
Drug | GlaxoSmithKline, LLC. | $21.19 | 1 | 2025 |
Source payment records
|
|||||
| AIRSUPRA Normalized: airsupra |
Drug | AstraZeneca Pharmaceuticals LP | $19.71 | 1 | 2025 |
Source payment records
|
|||||
| FREESTYLE LIBRE 3 Normalized: freestyle libre 3 |
Device | Abbott Laboratories | $15.91 | 1 | 2025 |
Source payment records
|
|||||
* Product-associated amounts are non-additive because one payment record may name more than one product.
These products were named on specific Open Payments records. A named product does not show that the payment influenced treatment or prescribing.
Public prescribing for products named in payments
| Open Payments product | Payment year | Part D brand | Part D year | Claims | Match method | Source |
|---|---|---|---|---|---|---|
| LINZESS linzess |
2025 | Linzess | 2024 | 62 | exact normalized | Medicare Part D |
| Ozempic ozempic |
2025 | Ozempic | 2024 | 20 Beneficiary count suppressed |
exact normalized | Medicare Part D |
The presence of the same drug in both datasets does not show that a payment caused or influenced a prescription.
Analysis 2 · Same-company prescribing overlap
Drugs reported in other payments from the same company that also appear in Medicare Part D
This analysis is independent from products named on this doctor’s individual payment records. A row appears only when the exact Open Payments reporting entity paid this doctor, that same reporting entity reported the drug or biological on at least 10 loaded General Payment records involving at least 2 distinct recipient NPIs, and this doctor has the same non-generic brand in public Part D data. This does not mean the company owns or manufactures the drug.
| Paying company | Payment year | Drug reported by same entity | Open Payments evidence | Part D | Claims | Beneficiaries |
|---|---|---|---|---|---|---|
| ABBVIE INC. Exact reporting entity; no affiliate inference |
2025 | LINZESS open payments reported associated product |
CMS Open Payments — General Payments 87954 supporting records · 21815 recipient NPIs · example record 1201352608 |
Linzess · 2024 Exact normalized brand match · 1 Part D row |
62 | 28 |
| AstraZeneca Pharmaceuticals LP Exact reporting entity; no affiliate inference |
2025 | FARXIGA open payments reported associated product |
CMS Open Payments — General Payments 106133 supporting records · 42906 recipient NPIs · example record 1206131362 |
Farxiga · 2024 Exact normalized brand match · 1 Part D row |
102 | 36 |
| AstraZeneca Pharmaceuticals LP Exact reporting entity; no affiliate inference |
2025 | SYMBICORT open payments reported associated product |
CMS Open Payments — General Payments 71 supporting records · 51 recipient NPIs · example record 1206132610 |
Symbicort · 2024 Exact normalized brand match · 1 Part D row |
12 | suppressed by CMS |
| Lilly USA, LLC Exact reporting entity; no affiliate inference |
2025 | JARDIANCE open payments reported associated product |
CMS Open Payments — General Payments 47708 supporting records · 23833 recipient NPIs · example record 1186464557 |
Jardiance · 2024 Exact normalized brand match · 1 Part D row |
266 | 78 |
| Lilly USA, LLC Exact reporting entity; no affiliate inference |
2025 | TRULICITY open payments reported associated product |
CMS Open Payments — General Payments 71 supporting records · 57 recipient NPIs · example record 1186464601 |
Trulicity · 2024 Exact normalized brand match · 1 Part D row |
23 | suppressed by CMS |
| Novo Nordisk Inc Exact reporting entity; no affiliate inference |
2025 | Ozempic open payments reported associated product |
CMS Open Payments — General Payments 261625 supporting records · 77793 recipient NPIs · example record 1188130076 |
Ozempic · 2024 Exact normalized brand match · 1 Part D row |
20 | suppressed by CMS |
These facts do not show that a payment was for the drug, that the company owns or manufactures the drug, or that a payment caused or influenced prescribing.
Public Medicare Part D data
Provider-and-drug rows loaded for 2024
| Brand | Generic | Claims | Beneficiaries |
|---|---|---|---|
| Atorvastatin Calcium | Atorvastatin Calcium | 639 | 279 |
| Losartan Potassium | Losartan Potassium | 444 | 186 |
| Metformin Hcl | Metformin Hcl | 398 | 183 |
| Amlodipine Besylate | Amlodipine Besylate | 332 | 165 |
| Januvia | Sitagliptin Phosphate | 276 | 75 |
| Jardiance | Empagliflozin | 266 | 78 |
| Famotidine | Famotidine | 264 | 133 |
| Metoprolol Succinate | Metoprolol Succinate | 264 | 132 |
| Montelukast Sodium | Montelukast Sodium | 227 | 134 |
| Omeprazole | Omeprazole | 221 | 112 |
| Gabapentin | Gabapentin | 218 | 105 |
| Levothyroxine Sodium | Levothyroxine Sodium | 190 | 91 |
| Tamsulosin Hcl | Tamsulosin Hcl | 186 | 91 |
| Lisinopril | Lisinopril | 171 | 80 |
| Albuterol Sulfate Hfa | Albuterol Sulfate | 146 | 80 |
| Ropinirole Hcl | Ropinirole Hcl | 145 | 72 |
| Simvastatin | Simvastatin | 133 | 63 |
| Diclofenac Sodium | Diclofenac Sodium | 111 | 77 |
| Kerendia | Finerenone | 109 | 36 |
| Clopidogrel | Clopidogrel Bisulfate | 106 | 50 |
| Farxiga | Dapagliflozin Propanediol | 102 | 36 |
| Basaglar Kwikpen U-100 | Insulin Glargine,hum.Rec.Anlog | 101 | 37 |
| Donepezil Hcl | Donepezil Hcl | 94 | 41 |
| Pantoprazole Sodium | Pantoprazole Sodium | 89 | 47 |
| Janumet | Sitagliptin Phos/Metformin Hcl | 88 | 29 |
| Fluticasone Propionate | Fluticasone Propionate | 87 | 67 |
| Nitrofurantoin Mono-Macro | Nitrofurantoin Monohyd/M-Cryst | 80 | 65 |
| Halobetasol Propionate | Halobetasol Propionate | 77 | 55 |
| Hydrochlorothiazide | Hydrochlorothiazide | 77 | 40 |
| Celecoxib | Celecoxib | 75 | 62 |
| Furosemide | Furosemide | 75 | 42 |
| Hydralazine Hcl | Hydralazine Hcl | 73 | 36 |
| Calcitriol | Calcitriol | 70 | 34 |
| Metoprolol Tartrate | Metoprolol Tartrate | 67 | 38 |
| Carvedilol | Carvedilol | 66 | 33 |
| Ammonium Lactate | Ammonium Lactate | 64 | 42 |
| Lantus Solostar | Insulin Glargine,hum.Rec.Anlog | 64 | 33 |
| Atenolol | Atenolol | 63 | 31 |
| Folic Acid | Folic Acid | 62 | 42 |
| Linzess | Linaclotide | 62 | 28 |
| Clobetasol Propionate | Clobetasol Propionate | 61 | 30 |
| Finasteride | Finasteride | 61 | 30 |
| Easy Touch Alcohol Prep Pads | Alcohol Antiseptic Pads | 57 | 33 |
| Glipizide | Glipizide | 57 | 28 |
| Losartan-Hydrochlorothiazide | Losartan/Hydrochlorothiazide | 56 | 26 |
| Trazodone Hcl | Trazodone Hcl | 54 | 28 |
| Alendronate Sodium | Alendronate Sodium | 51 | 33 |
| Rosuvastatin Calcium | Rosuvastatin Calcium | 51 | 25 |
| Glimepiride | Glimepiride | 50 | 23 |
| Vitamin D2 | Ergocalciferol (Vitamin D2) | 50 | 31 |
| Escitalopram Oxalate | Escitalopram Oxalate | 49 | 25 |
| Tradjenta | Linagliptin | 47 | 14 |
| Azithromycin | Azithromycin | 46 | 42 |
| Sertraline Hcl | Sertraline Hcl | 46 | 25 |
| Methocarbamol | Methocarbamol | 44 | 38 |
| Triamcinolone Acetonide | Triamcinolone Acetonide | 44 | 31 |
| Alcohol Prep Pads | Alcohol Antiseptic Pads | 43 | 31 |
| Meclizine Hcl | Meclizine Hcl | 43 | 21 |
| Lactulose | Lactulose | 41 | 19 |
| Clonazepam | Clonazepam | 38 | 25 |
| Clotrimazole-Betamethasone | Clotrimazole/Betamethasone Dip | 38 | 29 |
| Budesonide-Formoterol Fumarate | Budesonide/Formoterol Fumarate | 36 | 23 |
| Fenofibrate | Fenofibrate | 34 | 24 |
| Pioglitazone Hcl | Pioglitazone Hcl | 34 | 16 |
| Latanoprost | Latanoprost | 33 | 11 |
| Valsartan | Valsartan | 33 | 15 |
| Allopurinol | Allopurinol | 32 | 18 |
| Fluticasone-Salmeterol | Fluticasone Propion/Salmeterol | 32 | 16 |
| Glipizide Er | Glipizide | 32 | 20 |
| Pravastatin Sodium | Pravastatin Sodium | 32 | 15 |
| Ketoconazole | Ketoconazole | 31 | 20 |
| Loperamide | Loperamide Hcl | 31 | 18 |
| Mirtazapine | Mirtazapine | 31 | 13 |
| Chlorhexidine Gluconate | Chlorhexidine Gluconate | 30 | 29 |
| Metoclopramide Hcl | Metoclopramide Hcl | 30 | 18 |
| Novolog Flexpen | Insulin Aspart | 30 | 16 |
| Oxybutynin Chloride | Oxybutynin Chloride | 30 | 17 |
| Esomeprazole Magnesium | Esomeprazole Magnesium | 29 | 14 |
| Ranolazine Er | Ranolazine | 28 | 13 |
| Nortriptyline Hcl | Nortriptyline Hcl | 27 | 15 |
| Meloxicam | Meloxicam | 26 | 22 |
| Dicyclomine Hcl | Dicyclomine Hcl | 25 | 20 |
| Enalapril Maleate | Enalapril Maleate | 25 | 12 |
| Isosorbide Mononitrate Er | Isosorbide Mononitrate | 25 | 13 |
| Potassium Chloride | Potassium Chloride | 25 | 16 |
| Omeprazole-Sodium Bicarbonate | Omeprazole/Sodium Bicarbonate | 24 | 16 |
| Promethazine Hcl | Promethazine Hcl | 24 | 22 |
| Sucralfate | Sucralfate | 24 | 13 |
| Vascepa | Icosapent Ethyl | 24 | suppressed |
| Amitriptyline Hcl | Amitriptyline Hcl | 23 | suppressed |
| Procto-Med Hc | Hydrocortisone | 23 | 15 |
| Trulicity | Dulaglutide | 23 | suppressed |
| Amoxicillin | Amoxicillin | 22 | 20 |
| Hydroxyzine Hcl | Hydroxyzine Hcl | 22 | 16 |
| Ultra-Fine Mini Pen Needle | Pen Needle, Diabetic | 22 | suppressed |
| Entresto | Sacubitril/Valsartan | 21 | suppressed |
| Ezetimibe | Ezetimibe | 21 | suppressed |
| Lidocaine | Lidocaine | 20 | suppressed |
| Nifedipine Er | Nifedipine | 20 | suppressed |
| Novolog Mix 70-30 Flexpen | Insulin Aspart Prot/Insuln Asp | 20 | suppressed |
| Ondansetron Hcl | Ondansetron Hcl | 20 | 13 |
| Ozempic | Semaglutide | 20 | suppressed |
| Ramipril | Ramipril | 20 | suppressed |
| Eliquis | Apixaban | 19 | suppressed |
| Jentadueto | Linagliptin/Metformin Hcl | 19 | suppressed |
| Clonidine Hcl | Clonidine Hcl | 18 | suppressed |
| Fluoxetine Hcl | Fluoxetine Hcl | 18 | suppressed |
| Lovastatin | Lovastatin | 18 | suppressed |
| Cyanocobalamin Injection | Cyanocobalamin (Vitamin B-12) | 17 | suppressed |
| Olmesartan Medoxomil | Olmesartan Medoxomil | 17 | suppressed |
| Pregabalin | Pregabalin | 17 | suppressed |
| Propranolol Hcl | Propranolol Hcl | 17 | suppressed |
| Clotrimazole | Clotrimazole | 16 | suppressed |
| Tresiba Flextouch U-200 | Insulin Degludec | 16 | suppressed |
| Cilostazol | Cilostazol | 15 | suppressed |
| Pro Comfort Alcohol Pads | Alcohol Antiseptic Pads | 15 | 13 |
| Ultra-Fine Nano Pen Needle | Pen Needle, Diabetic | 15 | suppressed |
| Ventolin Hfa | Albuterol Sulfate | 15 | 12 |
| Baclofen | Baclofen | 14 | 11 |
| Colchicine | Colchicine | 13 | suppressed |
| Fluconazole | Fluconazole | 13 | 12 |
| Fluocinonide | Fluocinonide | 13 | suppressed |
| Metformin Hcl Er | Metformin Hcl | 13 | suppressed |
| Alprazolam | Alprazolam | 12 | suppressed |
| Diclofenac Potassium | Diclofenac Potassium | 12 | suppressed |
| Methylprednisolone | Methylprednisolone | 12 | 11 |
| Nitroglycerin | Nitroglycerin | 12 | suppressed |
| Symbicort | Budesonide/Formoterol Fumarate | 12 | suppressed |
| Zolpidem Tartrate | Zolpidem Tartrate | 12 | suppressed |
| Alcohol Swabs | Alcohol Antiseptic Pads | 11 | suppressed |
| Breo Ellipta | Fluticasone/Vilanterol | 11 | suppressed |
| Carbidopa-Levodopa | Carbidopa/Levodopa | 11 | suppressed |
| Cyproheptadine Hcl | Cyproheptadine Hcl | 11 | 11 |
| Ibuprofen | Ibuprofen | 11 | 11 |
Timeline
Payment and prescribing data by year
Open Payments and Medicare Part D may refer to different years. They are shown separately rather than aligned as if they describe the same period.
| Year | General Payments | Main payer | Explicit products | Company overlaps | Part D coverage |
|---|---|---|---|---|---|
| 2025 | $576.21 · 26 records | Phathom Pharmaceuticals, Inc. | ACCRUFER, AFREZZA, AIRSUPRA, BREZTRI, CREON, FREESTYLE LIBRE 3, LINZESS, MOUNJARO, OTEZLA, Ozempic, REPATHA, Rybelsus, TRELEGY ELLIPTA, VOQUEZNA, ZEPBOUND | 6 | — |
| 2024 | — | — | — | — | Complete |
Questions to ask
Questions you could discuss with your doctor
- What role, if any, does Linzess play in your treatment recommendations for me?
- How do you evaluate evidence when you have a financial relationship with ABBVIE INC.?
- Are there reasonable alternatives I should understand when we discuss treatment options?
- How should I interpret the industry-payment records shown here in the context of my care?
These are general questions generated from reviewed templates. They are not personalized medical advice.
Sources and limitations
How to read this page
- Payment and Medicare prescribing data can cover different years; every comparison shows both years explicitly.
- Part D does not represent a doctor’s entire practice; it excludes many patients and is subject to CMS public-release thresholds.
- Company–drug relationships must have an auditable source, a precise relationship type, and a valid evidence period. Unresolved mappings are not published.
- Generic drug claims are not attributed to a specific manufacturer without manufacturer-level evidence.
- When a source extract is incomplete, missing rows are never treated as proof of no payments or no prescriptions.
Loaded source releases
| Dataset | Year | Publication | Source |
|---|---|---|---|
| CMS Open Payments — General Payments | 2025 | 2026-06-30 | Original source |
| Medicare Part D Prescribers by Provider and Drug | 2024 | 2026-05-06 | Original source |
| NPPES Data Dissemination V2 | current / reference data | 2026-08-10 | Original source |
Full methodology · Questions & answers · Report a possible error